Ventricular tachycardia (VT): overview, causes, and management

Mechanism and characteristics

Normally, electrical impulses originate in the atria and travel to the ventricles through a coordinated conduction system (heart anatomy). In VT, an abnormal focus, re‑entry circuit, or triggered activity within the ventricular muscle produces a rapid ventricular rate. The heart rate in VT is usually well above a normal resting range of 60–100 beats per minute, often fast enough that the ventricles do not have adequate time to fill with blood between beats. On an electrocardiogram, VT typically shows wide QRS complexes and a regular rapid rhythm; clinicians distinguish monomorphic VT from polymorphic VT and non‑sustained from sustained forms.

Causes and risk factors

• Structural heart disease — prior heart attack, scar tissue, or cardiomyopathy.
• Ischemia — reduced coronary blood flow that can provoke ventricular arrhythmias.
• Electrolyte disturbances (for example, abnormal potassium or magnesium).
• Drug effects or toxicity (some medications and stimulants).
• Inherited channelopathies and certain genetic syndromes.

These conditions change the electrical properties of the ventricular muscle and increase the chance of rapid, disorganized beating that can reduce cardiac output and cause hypotension (low blood pressure).

Clinical presentation and complications

Symptoms depend on the rate, duration, and underlying heart function. VT may cause palpitations, lightheadedness, chest pain, shortness of breath, or collapse. When the ventricles beat too rapidly, vital organs such as the brain receive less blood and oxygen, which can lead to fainting or altered mental status. VT can degenerate into ventricular fibrillation, progress to cardiac arrest, or result in sudden death if not rapidly treated.

Diagnosis and initial management

Diagnosis relies on clinical assessment and an electrocardiogram. In emergencies, securing the airway, breathing, and circulation is paramount. Immediate treatment depends on the patient's stability: unstable patients with severe symptoms or hypotension usually require prompt synchronized cardioversion or defibrillation. Stable patients may be managed with antiarrhythmic medications and monitoring while reversible causes (electrolyte imbalances, ischemia, drug effects) are corrected.

Long‑term treatment and prevention

• Implantable cardioverter‑defibrillators (ICDs) for patients at high risk of recurrent VT or sudden cardiac death.
• Catheter ablation targeting the arrhythmia focus for recurrent or drug‑refractory VT.
• Medications such as beta blockers or antiarrhythmics to reduce episodes.
• Management of underlying heart disease, lifestyle modification, and correction of metabolic causes.

Prognosis varies with the cause, the frequency of episodes, and how quickly treatment is provided. Early recognition, appropriate emergency response, and targeted long‑term strategies can markedly improve outcomes for people with ventricular tachycardia. For further information on related topics, see resources on tachycardia basics, heart structure (anatomy), emergency care (acute management), and complications such as ventricular fibrillation and sudden cardiac death.

Additional practical references include guidance on monitoring heart rate (normal and abnormal rates), maintaining circulatory volume (blood flow), recognizing hypotension (blood pressure), protecting organ perfusion (brain and oxygen delivery), and avoiding triggers that may precipitate ventricular arrhythmias.